Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20163586 | 1.00 | GPR183 (0.34) | GPR183MEN1KMT2ATRPV1KCNH2 | |
| SCHEMBL20163419 | 0.98 | GPR183 (0.32) | GPR183MEN1KMT2ATRPV1 | |
| SCHEMBL20163403 | 0.98 | GPR183 (0.32) | GPR183MEN1KMT2ATRPV1 | |
| SCHEMBL20163407 | 0.98 | GPR183 (0.32) | GPR183MEN1KMT2ATRPV1 | |
| SCHEMBL20163425 | 0.98 | GPR183 (0.32) | GPR183MEN1KMT2ATRPV1 | |
| SCHEMBL20163347 | 0.91 | RAB9A (0.37) | MEN1KMT2A | |
| SCHEMBL20163344 | 0.91 | RAB9A (0.37) | MEN1KMT2A | |
| SCHEMBL20173481 | 0.87 | GPR183 (0.33) | GPR183MEN1KMT2A | |
| SCHEMBL20173479 | 0.85 | MEN1 (0.33) | GPR183MEN1KMT2A | |
| SCHEMBL20163534 | 0.85 | MEN1 (0.33) | GPR183MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200255415-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-08-13 | — | — | US | disclosed |
| EP-3544974-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | Eisai R&D Management Co., Ltd. (JP) | 2019-10-02 | — | — | EP | disclosed |
| WO-2018098305-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-05-31 | — | — | WO | disclosed |
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2018-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141913-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE | BRCA1, ESR2, ESR1 | GPR183 161/4885MEN1 3869/4885KMT2A 3295/4885 |
| US-20200255415-A1 | TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF BREAST CANCER | BRCA1, ESR2, ESR1 | GPR183 154/4885MEN1 4136/4885KMT2A 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.